Phase I/II study of paclitaxel+carboplatin for refractory or recurrent non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3083-3087

  Gemma, Akihiko ^a   Seike, Masahiro ^a   Kosaihira, Seiji ^a   Minegishi, Yuji ^a   Noro, Rintaro ^a   Nara, Michiya ^a   Hosomi, Yukio ^a   Okano, Tetsuya ^a   Kokubo, Yutaka ^a   Yoshimura, Akinobu ^a   Shibuya, Masahiko ^b   Kudoh, Shoji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel; Refractory or recurrent cases

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARBOPLATIN PLUS PACLITAXEL; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NAVELBINE; PACLITAXEL; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT CANCER; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PILOT PROJECTS;

EID: 33746746452     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Murray N, Livingston RB, Shepherd FA et al: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17: 2300-2308, 1999.
2. Ayash LJ, Elias A, Wheeler C et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12: 37-44, 1994.
3. Fukuoka M, Furuse K, Saijo N et al: Randomized trial of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855-861, 1991.
4. Roth BJ, Johnson DH, Einhorn LH et al: Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282-291, 1992.
5. Salmon SE: Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 68: 117-125, 1984.
6. Bogden AE and Von Hoff DD: Comparison of the human tumor cloning and subrenal capsule assays. Cancer Res 44: 1087-1090, 1984.
7. Schiller JH, Harrington D, Belani CP et al: Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
8. Bonomi P, Kim K, Fairclough D et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000.
9. Shepherd FA, Dancey J, Ramlau R et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
10. Smit EF, Mattson K, von Pawel J et al: ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14: 455-460, 2003.
11. Alberola V, Camps C, Provencio M et al: Spanish Lung Cancer Group. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21: 3207-3213, 2003.
12. Miller VA, Johnson DH, Krug LM et al: Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 21: 2094-2100, 2003.
13. Georgoulias V, Papadakis E, Alexopoulos A et al: Greek Oncology Cooperative Group (GOCG) for lung cancer. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357: 1478-1484, 2001.
14. Schmittel A, Siehl JM, Schulze M et al: Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients. Anticancer Res 25(2B): 1333-1336, 2005.
15. Eisen MB and Brown PO: DNA arrays for analysis of gene expression. Methods Enzymol 303: 179-205, 1999.
16. Ross DT, Scherf U, Eisen MB et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235, 2000.
17. Eisen MB, Spellman PT, Brown PO et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
18. Scherf U, Ross DT, Waltham M et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-44, 2000.
19. Gemma A, Li C, Matsuda K, Seike M et al: Chemotherapy strategy design based on gene expression profiles and sensitivity database and a phase I/II study of paclitaxel + carboplatin regimen in the chemotherapy for refractory or recurrent non-small cell lung cancer (NSCLC). Int J Clin Oncol 39: 731, 2004
20. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, Switzerland, WHO, 1979.
21. Seidman AD, Hudis CA, Albanel J et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
22. Akiyama Y, Ohe Y, Tamura T et al: A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 31: 482-487, 2001.
23. Belani CP, Barstis J, Perry MC et al: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21: 2933-2939, 2003.
24. Numico G, Colantonio I, Gasco M et al: Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res 25(3): 2555-2559, 2005.